NLSP
Price:
$1.857
Market Cap:
$4.59M
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.[Read more]
Industry
Biotechnology
IPO Date
2021-01-29
Stock Exchange
NASDAQ
Ticker
NLSP
According to NLS Pharmaceutics AG’s latest financial reports and current stock price. The company's current PE Ratio is -0.28. This represents a change of -100.00% compared to the average of -10490.53 of the last 4 quarters.
The mean historical PE Ratio of NLS Pharmaceutics AG over the last ten years is -155.77. The current -0.28 PE Ratio has changed -82.03% with respect to the historical average. Over the past ten years (40 quarters), NLSP's PE Ratio was at its highest in in the June 2022 quarter at -10.80. The PE Ratio was at its lowest in in the June 2018 quarter at -155129.77.
Average
-155.77
Median
-194.70
Minimum
-264.57
Maximum
-54.82
Discovering the peaks and valleys of NLS Pharmaceutics AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 29.35%
Maximum Annual PE Ratio = -54.82
Minimum Annual Increase = -71.85%
Minimum Annual PE Ratio = -264.57
Year | PE Ratio | Change |
---|---|---|
2023 | -73.77 | 19.81% |
2022 | -61.57 | 12.32% |
2021 | -54.82 | -71.85% |
2020 | -194.70 | -17.66% |
2019 | -236.45 | -10.63% |
2018 | -264.57 | 29.35% |
The current PE Ratio of NLS Pharmaceutics AG (NLSP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-63.38
5-year avg
-124.26
10-year avg
-155.77
NLS Pharmaceutics AG’s PE Ratio is greater than NeuroBo Pharmaceuticals, Inc. (-0.87), greater than Indaptus Therapeutics, Inc. (-0.59), less than Pasithea Therapeutics Corp. (-0.17), less than Quoin Pharmaceuticals, Ltd. (-0.28), greater than Lixte Biotechnology Holdings, Inc. (-1.18), greater than Anebulo Pharmaceuticals, Inc. (-5.53), greater than NervGen Pharma Corp. (-9.07), greater than Acrivon Therapeutics, Inc. Common Stock (-3.08), greater than Protagenic Therapeutics, Inc. (-0.40), greater than Miromatrix Medical Inc. (-7.13), greater than Rezolute, Inc. (-4.41), greater than HCW Biologics Inc. (-0.40), less than Eliem Therapeutics, Inc. (0), greater than Molecular Partners AG (-2.46), greater than Assembly Biosciences, Inc. (-2.30), greater than Neoleukin Therapeutics, Inc. (-5.86), greater than Instil Bio, Inc. (-1.87), less than CytomX Therapeutics, Inc. (6.58), greater than Achilles Therapeutics plc (-0.69),
Company | PE Ratio | Market cap |
---|---|---|
-0.87 | $20.33M | |
-0.59 | $11.18M | |
-0.17 | $3.27M | |
-0.28 | $2.45M | |
-1.18 | $4.70M | |
-5.53 | $43.83M | |
-9.07 | $152.57M | |
-3.08 | $193.67M | |
-0.40 | $3.35M | |
-7.13 | $92.95M | |
-4.41 | $253.78M | |
-0.40 | $14.76M | |
0 | $342.68M | |
-2.46 | $195.74M | |
-2.30 | $93.95M | |
-5.86 | $8.20M | |
-1.87 | $140.89M | |
6.58 | $83.74M | |
-0.69 | $46.85M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NLS Pharmaceutics AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NLS Pharmaceutics AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NLS Pharmaceutics AG's PE Ratio?
How is the PE Ratio calculated for NLS Pharmaceutics AG (NLSP)?
What is the highest PE Ratio for NLS Pharmaceutics AG (NLSP)?
What is the 3-year average PE Ratio for NLS Pharmaceutics AG (NLSP)?
What is the 5-year average PE Ratio for NLS Pharmaceutics AG (NLSP)?
How does the current PE Ratio for NLS Pharmaceutics AG (NLSP) compare to its historical average?